Sorry I was a little unclear in the message...the deal with Merck with ASONEP is for all applications...of course...

"Under the terms of the agreement, Merck Serono will provide Lpath up to $23 million of upfront payments and R&D funding to support Lpath's completion of the Phase I clinical trial. If Merck Serono accepts the responsibility to develop ASONEP beyond Phase I, it will pay Lpath an additional $28 million and will fund all continuing development activities. Further payments will be made on achievement of development, regulatory, and sales milestones that could total up to $422 million should ASONEP be approved in multiple indications.

As part of the alliance, Merck Serono now has exclusive, worldwide rights to develop and commercialize ASONEP across all indications and Lpath will receive royalties on commercial sales of the product. "